GENE: gtglabs.com Projected Price to Earnings

GENE (gtglabs.com) - company brandmark

The forward P/E ratio of Genetic Technologies (GENE) reflects the impact of geopolitical barriers and logistics disruptions on diagnostics exports, with the value holding at 0.00. Stability is supported by the scaling of cancer test sales, which reduces unit costs. High pricing power, driven by the uniqueness of polygenic health risk analysis, creates a foundation of resilience for Genetic Technologies (GENE).

Market Cap to Projected Earnings: Genetic Technologies (GENE) for 07/04/2022 - 10/26/2024

Analytical breakdowns and data insights for company GTG Labs (GENE)

- stock value and consensus price forecast:
Price Chart Genetic Technologies|GENE - Price Target Chart
- market capitalization information:
Market Valuation Genetic Technologies Ltd|GENE - Total Enterprise Value
- issuer book value statistics:
Net Assets per Single Share Genetic Technologies|GENE - Book Valuation of Business|Market Capitalization to Book Value Ratio gtglabs.com|GENE - Company Total Asset Base
- debt level and financial liquidity data:
Debt to Equity Genetic Technologies|GENE - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Capital Genetic Technologies|GENE - Company Total Indebtedness|Debts to Book Capitalization Genetic Technologies Ltd|GENE - Long-Term Debt|Company Short-Term Debt Genetic Technologies|Quick Ratio gtglabs.com
- company profitability and valuation multiples indicators:
GENE - Company Net Income|Future Profit Genetic Technologies|GENE - Market Price to Net Income Ratio|Forward P/E Multiple Genetic Technologies|GENE - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple Genetic Technologies Ltd|GENE - Operating profit before deduction of amortization|Net earnings per share for the last 12 months Genetic Technologies|GENE - Earnings per share for the trailing year|Year-over-year net earnings per share growth for the last 12 months gtglabs.com|GENE - Net earnings per one share growth for the current year|Earnings growth forecast for next year Genetic Technologies
Initial company analysis:Genetic Technologies Limited
Signature product of GTG Labs

The forward P/E reflects the ratio of the asset's current market value to expected earnings, allowing for an assessment of the premium paid for potential revenue growth. By analyzing the forward P/E of Genetic Technologies (GENE), an investor determines the fairness of the price considering the implementation of diagnostic panels in clinics, which creates a sustainable revenue stream through the use of Genetic Technologies (GENE) patented biomarkers.

Competitors of Genetic Technologies (GENE)

Future Price to Earnings Agilent (A)|Future Price to Earnings DGX (Quest Diagnostics Inc.)|Illumina Corp - Projected Price to Earnings|Exact Sciences Inc. (EXAS) - Projected Price to Earnings Ratio|RVTY - Future Price to Earnings|Market Cap to Projected Earnings bio-rad.com BIO|NNNN: Forward P/E Multiple|SHC - Market Cap to Projected Earnings|Future Price to Earnings QuidelOrtho Corp|OPKO Health Corp. (OPK) - Market Cap to Projected Earnings|Forward P/E Multiple CDNA|maravai.com (MRVI) - Forward Price to Earnings Multiple|Forward P/E Multiple FLGT (Fulgent Genetics)|Standard BioTools Inc (LAB) - Projected Price to Earnings Ratio|CTKB - Future Price to Earnings|OSUR (OraSure Corp) - Price to Future Earnings Ratio|XGN: Forward P/E Multiple|Projected Price to Earnings Ratio mdxhealth.com (MDXH)|Projected Price to Earnings LUCD|PRE (Prenetics Global Ltd) - Market Cap to Future Earnings Ratio|Forward P/E Multiple IMDX|Market Cap to Projected Earnings trinitybiotech.com|Forward P/E Multiple PRPH (ProPhase Labs, Inc.)|AIMD - Projected Price to Earnings|CODX: Projected Price to Earnings|Future Price to Earnings Multiple HSCS (Heart Test Laboratories, Inc.)|BMRA (Biomerica, Inc) - Projected Price to Earnings|CDIO: Market Cap to Future Earnings Ratio|ONCO (Onconetix, Inc.) - Forward P/E Multiple|Projected Price to Earnings Ratio viraxbiolabs.com VRAX|Forward P/E Multiple BJDX|Projected Price to Earnings Aspira Women's Health, Inc. AWH|Forward P/E Multiple AXDX (Accelerate Diagnostics, Inc)|Future Price to Earnings Multiple CNTG|ENZ - Future Price to Earnings|FRES (Fresh2 Group Limited) - Price to Future Earnings Ratio|23andMe (ME) - Future Price to Earnings|Projected Price to Earnings Ratio Psychemedics Corp. (PMD)